2009
Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514
Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie S, Armand J, Shepherd F, Herbst R. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Journal Of Clinical Oncology 2009, 27: 8098-8098. DOI: 10.1200/jco.2009.27.15_suppl.8098.Peer-Reviewed Original ResearchBMS-690514Skin rashPD biomarkersSkin biopsiesKRAS mutationsPhase I/II studyNon-small cell lung cancer patientsReversible acute renal insufficiencyRandomized phase II trialCell lung cancer patientsEGFR T790M mutationAdequate organ functionOral selective inhibitorDisease control rateAcute renal insufficiencyPhase I portionPhase II trialLung cancer patientsT790M mutationSubsequent surgical removalAnti-tumor activityEGFR copy numberEGFR T790MECOG PSEligible patients
2005
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2005, 23: 5578-5587. PMID: 16009949, DOI: 10.1200/jco.2005.07.120.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionDrug Administration ScheduleFemaleFluorouracilHead and Neck NeoplasmsHumansLogistic ModelsMaleMiddle AgedNeoplasm Recurrence, LocalPaclitaxelSurvival AnalysisTreatment OutcomeConceptsSquamous cell carcinomaSkin rashCell carcinomaAcne-like skin rashMulticenter phase II studyPhase II multicenter studyRefractory squamous cell carcinomaMedian overall survival timeEpidermal growth factor receptor antibody cetuximabRecurrent squamous cell carcinomaCisplatin/fluorouracilCisplatin/paclitaxelSafety of cetuximabPhase II studyMajority of patientsOverall survival timePlatinum-based therapySingle-agent trialsSerious allergic reactionsMurine monoclonal antibodiesActive regimenStable diseaseCommon toxicitiesII studyMedian duration
2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
Herbst R, Kim E, Harari P. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-732. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Anti-epidermal growth factor receptor monoclonal antibodyAnti-EGFR monoclonal antibodiesMonoclonal antibodiesLocoregional disease recurrenceImportant adverse eventsPhase I studiesReceptor monoclonal antibodyExcellent response ratesTreatment of headHuman tumor xenograftsExtracellular receptor sitesInhibition of metastasisEnhanced tumor invasionPotent antitumour activityAnticancer treatment strategiesGrowth factor receptorCancer cell linesAdverse eventsRefractory diseaseSkin rashWeekly infusionsDisease recurrence